Mitochondrial-derived peptides as a novel intervention for obesity and cardiac diseases: bench evidence for potential...

Currently, obesity is the most common major health problem for people worldwide. Obesity is known to be a significant risk factor for several diseases, including metabolic syndrome, insulin resistance and type 2 diabetes, eventually leading to the development of chronic systemic disorders. Previous studies showed that mitochondrial dysfunction could be one of the potential mechanisms for obesity progression. Most interventions used for combating obesity have also been reported to modulate mitochondrial function, suggesting the potential role of mitochondria in the pathology of the obese condition. Recent studies have shown that peptides produced by mitochondria, mitochondrial-derived peptides (MDPs), potentially improve metabolic function and exert benefits in obesity-associated diabetes and various heart pathologies. In this review, the roles of MDPs in the metabolic pathways and their use in the treatment of various adverse effects of obesity are comprehensively summarised based on collective evidence from in vitro, in vivo and clinical studies. The roles of MDPs as novel therapeutic interventions for cardiac dysfunction caused by various stresses or toxicities are also presented and discussed. This review aims to summarise the knowledge regarding the effects of MDPs on obesity, with a particular emphasis on their potential protective effects on the impaired cardiac function associated with obesity. The information from this review will also encourage further clinical investigations to warrant the potential application of MDP interventions in the clinical setting in the future.